Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report

Seventy-nine patients with metastatic melanoma received chlorozotocin (150 mg/m2) every 6 weeks. Two complete and five partial responses were observed: 18% in patients who had not previously received chemotherapy and 6% in previously drug-resistant patients. Dose-limiting toxic effects were vomiting and myelosuppression.